YAMNIUK; Aaron

Patent Applications and Registrations

Patent applications and USPTO patent grants for YAMNIUK; Aaron.The latest application filed is for "antagonistic cd40 monoclonal antibodies and uses thereof".

Company Profile

7.13.19

YAMNIUK; Aaron - Vancouver CA
YAMNIUK; Aaron - Vancouver BC CA
Yamniuk; Aaron - Lawrenceville NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof App 20220177596 - YAMNIUK; Aaron ; et al.	2022-06-09
Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof App 20220169742 - YAMNIUK; Aaron ; et al.	2022-06-02
Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof App 20220153856 - YAMNIUK; Aaron ; et al.	2022-05-19
Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof App 20220144962 - YAMNIUK; Aaron ; et al.	2022-05-12
Antibody Polypeptides That Antagonize Cd40l App 20220073636 - NADLER; Steven G. ; et al.	2022-03-10
Antagonistic CD40 monoclonal antibodies and uses thereof Grant 11,261,258 - Yamniuk , et al. March 1, 2	2022-03-01
Antagonistic CD40 monoclonal antibodies and uses in treating immune responses Grant 11,254,750 - Yamniuk , et al. February 22, 2	2022-02-22
Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity Grant 11,220,550 - Yamniuk , et al. January 11, 2	2022-01-11
Antibody polypeptides that antagonize CD40L Grant 11,180,567 - Nadler , et al. November 23, 2	2021-11-23
Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40 Grant 11,136,406 - Suri , et al. October 5, 2	2021-10-05
Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof App 20210054090 - YAMNIUK; Aaron ; et al.	2021-02-25
Methods Of Treating Immune Diseases By Administering Antibody Polypeptides That Antagonize Cd40 App 20200199244 - SURI; Anish ; et al.	2020-06-25
Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof App 20200157233 - YAMNIUK; Aaron ; et al.	2020-05-21
MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH App 20200148779 - YAMNIUK; Aaron ; et al.	2020-05-14
Nucleic acids encoding antibody polypeptides that antagonize CD40 Grant 10,544,228 - Suri , et al. Ja	2020-01-28
Antibody Polypeptides That Antagonize Cd40l App 20190100595 - NADLER; Steven G. ; et al.	2019-04-04
Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L Grant 10,196,451 - Nadler , et al. Fe	2019-02-05
Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof App 20180340031 - Yamniuk; Aaron ; et al.	2018-11-29
Antibody Polypeptides That Antagonize Cd40l App 20180051091 - NADLER; Steven G. ; et al.	2018-02-22
Antibody polypeptides that antagonize CD40L Grant 9,765,150 - Nadler , et al. September 19, 2	2017-09-19
Antibody Polypeptides That Antagonize Cd40 App 20170015754 - SURI; Anish ; et al.	2017-01-19
Antibody polypeptides that antagonize CD40 Grant 9,475,879 - Suri , et al. October 25, 2	2016-10-25
Antibody Polypeptides That Antagonize Cd40l App 20160075790 - NADLER; Steven G. ; et al.	2016-03-17
Antibody polypeptides that antagonize CD40L Grant 9,228,018 - Nadler , et al. January 5, 2	2016-01-05
Nucleic acids encoding antibody polypeptides that antagonize CD40L Grant 8,981,072 - Nadler , et al. March 17, 2	2015-03-17
Antibody Polypeptides That Antagonize Cd40l App 20150023976 - NADLER; Steven G. ; et al.	2015-01-22
Antibody polypeptides that antagonize CD40L Grant 8,895,010 - Nadler , et al. November 25, 2	2014-11-25
Antibody Polypeptides That Antagonize Cd40l App 20140099707 - NADLER; Steven G. ; et al.	2014-04-10
Antibody Polypeptides That Antagonize Cd40 App 20140099317 - Suri; Anish ; et al.	2014-04-10
Antibody Polypeptides That Antagonize Cd40l App 20130095109 - NADLER; Steven G. ; et al.	2013-04-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.